Summary
Eli Lilly and Company (LLY) announced on February 20, 2014, its entry into an Underwriting Agreement to issue and sell a total of $1 billion in aggregate principal amount of senior notes. This debt offering consists of $600 million of 1.950% Notes due 2019 and $400 million of 4.650% Notes due 2044. The offering was registered on a Form S-3 filing. This move indicates the company's strategy to secure long-term financing, likely to support its ongoing operations, research and development activities, or potential strategic initiatives. Investors can expect net proceeds of approximately $992.8 million after underwriter discounts but before other offering expenses. The issuance of these notes diversifies the company's debt structure and extends its maturity profile. The specific terms of the notes, including interest rates and maturity dates, are clearly defined, providing transparency regarding the cost of this new debt and the repayment schedule.
Key Highlights
- 1Eli Lilly issued $600 million in 1.950% Notes due 2019 and $400 million in 4.650% Notes due 2044.
- 2The total aggregate principal amount of the debt issuance is $1 billion.
- 3The offering is backed by a Form S-3 registration statement (File No. 333-186979).
- 4Net proceeds from the offering are estimated to be approximately $992.8 million.
- 5The issuance is intended to provide Eli Lilly with additional capital and diversify its debt maturities.
- 6The notes are governed by an Indenture dated February 1, 1991, with Deutsche Bank Trust Company Americas as trustee.
- 7The filing specifies the interest rates, maturity dates, and redemption provisions for both series of notes.